Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | ABL1 | P00519 | 14/20 | 0.51 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5845306 | 0.87 | HSD17B10 (0.52) | CYP3A4ALOX15HSD17B10ABL1CYP1A1 | |
| SCHEMBL5842729 | 0.83 | ALOX15 (0.55) | CYP3A4ALOX15HSD17B10ABL1SLC9A1 | |
| SCHEMBL5843743 | 0.83 | HSD17B10 (0.55) | CYP3A4ALOX15HSD17B10ABL1CYP1A1 | |
| SCHEMBL23137331 | 0.82 | ALOX15 (0.64) | CYP3A4ALOX15HSD17B10ABL1ALDH1A1 | |
| SCHEMBL6373101 | 0.81 | HSD17B10 (0.48) | CYP3A4ALOX15HSD17B10ABL1ALDH1A1 | |
| SCHEMBL5843781 | 0.80 | CYP3A4 (0.52) | CYP3A4ALOX15HSD17B10ABL1NPC1 | |
| SCHEMBL5845543 | 0.80 | CYP3A4 (0.52) | CYP3A4ALOX15HSD17B10ABL1ALDH1A1 | |
| SCHEMBL5843640 | 0.79 | HSD17B10 (0.55) | CYP3A4ALOX15HSD17B10ALDH1A1 | |
| SCHEMBL27909896 | 0.79 | ABL1 (0.47) | HSD17B10ABL1ALDH1A1 | |
| SCHEMBL26976334 | 0.79 | ALOX15 (0.59) | CYP3A4ALOX15HSD17B10ABL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7122061-B2 | Agents for dyeing keratin fibers, containing 4-aminobiphenyl-3-ol-derivatives | WELLA AG (DE) | 2006-10-17 | — | — | US | claimed |
| EP-1562539-A1 | AGENTS FOR DYEING KERATIN FIBERS, CONTAINING 4-AMINO-BIPHENYL-3-OL-DERIVATIVES | Wella Aktiengesellschaft (DE) | 2005-08-17 | — | — | EP | claimed |
| US-20050155160-A1 | Agents for dyeing keratin fibers, containing 4-amino-biphenyl-3-ol-derivatives | WELLA AKTIENGESELLSCHAFT (DE) | 2005-07-21 | — | — | US | claimed |
| WO-2004041226-A1 | AGENTS FOR DYEING KERATIN FIBERS, CONTAINING 4-AMINO-BIPHENYL-3-OL-DERIVATIVES | WELLA AKTIENGESELLSCHAFT (DE) | 2004-05-21 | — | — | WO | claimed |
| EP-1562539-A1 | AGENTS FOR DYEING KERATIN FIBERS, CONTAINING 4-AMINO-BIPHENYL-3-OL-DERIVATIVES | Wella Aktiengesellschaft (DE) | 2005-08-17 | — | — | EP | disclosed |
| US-20050155160-A1 | Agents for dyeing keratin fibers, containing 4-amino-biphenyl-3-ol-derivatives | WELLA AKTIENGESELLSCHAFT (DE) | 2005-07-21 | — | — | US | disclosed |
| WO-2004041226-A1 | AGENTS FOR DYEING KERATIN FIBERS, CONTAINING 4-AMINO-BIPHENYL-3-OL-DERIVATIVES | WELLA AKTIENGESELLSCHAFT (DE) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050155160-A1 | Agents for dyeing keratin fibers, containing 4-amino-biphenyl-3-ol-derivatives | KRT18, CBR3, CCNB3 | CYP3A4 835/4885ALOX15 3006/4885HSD17B10 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.